University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT06419335
This study includes an open label clinical trial comparing two doses of CoQ10 for 8 weeks to improve fatigue among patients with Crohn's disease and a prospective cohort study of healthy controls taking CoQ10 for 2 weeks. Additionally, among 15 participants who do not meet the fatigue threshold for the open label trial, the investigators will measure CoQ10 levels in blood and fasting urine, as well as complete the same data collection.
Hypotheses
1. Fatigue will improve with CoQ10 and there will be a dose response with greater improvement with higher dose as measured by the Patient Reported Outcomes Measurement Information Systems Fatigue PROMIS Fatigue 7a instrument. 2. Fatigue will improve when measured with other fatigue scales in a similar dose dependent manner and that general and physical fatigue will improve more than mental fatigue. 3. CoQ10 will improve quality of life as measured with the short Inflammatory Bowel Disease Questionnaire (sIBDQ).
This study is active but is not currently recruiting participants.
Notify Me18 year–70 year
All sexes
Interventional
Early Phase 1
Philadelphia, Pennsylvania, 19104, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for all study participants
To be eligible for this study all study participants must meet the following:
Additional inclusion criteria for Cohort 1 and Cohort 2 participants:
Exclusion criteria
- for all study participants
Exclusion criteria
for Cohorts 1 and 3
The core component of this pilot study will be a single center open label randomized trial comparing low dose and high dose CoQ10 among 30 patients with Crohn's disease and fatigue (Cohort 1) and 15 healthy volunteers (Cohort 3).
Time frame: 8 weeks
The primary objective of this study is to assess whether there is sufficient evidence of a change (greater than 7 points) in fatigue among patients with Crohn's disease taking CoQ10 to warrant conduct of a larger, placebo-controlled clinical trial. The primary outcome will be measured with the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue 7a, a unidimensional scale that has been well validated and tested among the general population and patients with IBD and many other chronic disorders. The scale ranges from 33.7 to 75.8. Higher scores indicate more greater fatigue.
Time frame: 8 weeks
Secondary outcome measures will include improvement in domain specific fatigue, overall fatigue assessed with a different unidimensional scale using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) for changes in Inflammatory Bowel Disease(IBD)-related quality of life. The scale ranges from 0 to 52. Higher scores indicate better quality of life.
University of Pennsylvania
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06197334
Crohn Disease, Digestive System Diseases
Vandœuvre-lès-Nancy, CHRU de Nancy, France
View Trial DetailsNCT07219537
Colonic Diseases, Colorectal Neoplasms
Boston, Massachusetts, United States
View Trial DetailsNCT07033208
Crohn Disease, Digestive System Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT05633706
Celiac Disease, Colitis
Calgary, Alberta, Canada
View Trial Details